Kimberly-Clark Corporation

← Main Page Análisis Graham Buffett Sowell Metodología About

Buffettology Investment Analysis

⚠️ HOLD — Income Investment, Not Growth

Projected total return ~10.9% (incl. dividends) — below Buffett's 15% threshold but strong income characteristics

Buffett Intrinsic Value Thermometer

◄ STRONG BUY ►◄ BUY ►◄ HOLD ►◄ OVERVALUED ►

Durable Competitive Advantage

Does KMB possess a consumer monopoly with predictable earnings and high returns on reinvested capital?

Consumer Monopoly Characteristics: KMB holds #1 or #2 brand positions in diapers (Huggies), tissue (Kleenex), feminine care (Kotex), and adult care (Depend). These are repeat-purchase necessities with strong brand loyalty. Consumers don't switch brands for tissue/diapers based on price alone — this is a consumer monopoly.

However: The company shows near-ZERO earnings growth over the past decade ($5.99 EPS in 2016 vs. $6.07 in 2025). This is a mature franchise returning cash via dividends rather than compounding reinvested earnings. Buffett prefers companies that RETAIN and REINVEST at 15%+ — KMB pays out 80%+ of earnings as dividends.

CAUTIONConsumer monopoly characteristics present, but near-zero growth disqualifies it as a Buffett compounder. Better suited as an income investment.

Sources: macrotrends.net EPS history (Jul 2026), marketbeat.com dividend data (Jul 16, 2026)

Initial Rate of Return (IRR)

Calculation: IRR = $6.07 ÷ $108.35 × 100 = 5.6%. This is at the LOW end of Buffett's 5-20% acceptable range. The company retains only ~20% of earnings (80% payout ratio), meaning very little is being reinvested for compounding.

Dividend Return: The 4.81% dividend yield provides immediate cash return, making this essentially a bond-like investment with modest growth.

CAUTIONIRR of 5.6% is marginal. Low retention limits compounding potential.

CAGR Analysis

Metric 5-Year CAGR 10-Year CAGR Buffett Minimum Result

Analysis: KMB fails ALL CAGR tests decisively. Revenue has DECLINED due to divestitures (IFP segment sold to Arbex JV). Net income and EPS have been essentially flat over a decade. This is NOT a growth company by any definition.

Context: The revenue decline is partly structural (deliberate portfolio pruning). Post-transformation, management targets mid-single-digit organic growth. Even at 6% forward growth, KMB would not reach Buffett's 15% threshold.

Income Statement Deep Dive

Gross Margin: At 36%, KMB falls BELOW Buffett's 40% threshold for durable competitive advantage. This reflects the commodity nature of tissue/paper products. PG achieves ~50%+ GPM for comparison.

SGA/GP: At 59.6%, this FAR exceeds the 30% ideal. KMB spends heavily on marketing and distribution to defend brand positions — a sign of competitive pressure.

Depreciation/GP: At 13.6%, this PASSES the <25% test. Capital requirements are moderate relative to gross profit.

Interest/Operating Income: At 10.9%, this barely exceeds the 10% threshold. Borderline.

Earning Power: Net Earnings $2,021M ÷ Revenue $16,447M × 100 = 12.3%. Adequate but not exceptional.

MIXEDDepreciation passes, but GPM below 40% and SGA/GP above 30% indicate competitive pressure on margins.

Balance Sheet Analysis

Cash Position: $688M cash vs. $7.2B total debt — significantly more debt than cash. Buffett's test: "Lots of cash + low debt = growth potential" — KMB FAILS this.

ROA: Net Income $2,021M ÷ Total Assets $17,098M = 11.8%. Adequate for consumer staples but not exceptional.

Goodwill: $1.84B in goodwill, relatively stable over time. Not excessive relative to total assets.

CAUTIONLow cash relative to debt. ROA is acceptable but not exceptional.

Debt Analysis

Debt Payoff: $6,474M LT debt ÷ $2,044M avg net income = 3.2 years. PASSES the 3-4 year test.

D/E Ratio: Raw D/E of 9.3x looks alarming, but this is misleading. $6.0B in treasury stock from decades of buybacks has depleted equity. Treasury-adjusted D/E: $15.4B ÷ ($1.65B + $6.0B) = 2.02x — still above Buffett's 0.80 ideal but explainable.

Deleveraging Trend: Total debt reduced from $8.6B (2021) to $7.2B (2025) — $1.4B reduction in 4 years. Positive trajectory.

CAUTIONDebt payoff passes (3.2 yrs) but treasury-adjusted D/E of 2.02 exceeds 0.80 threshold. Debt is manageable but not conservative.

Shareholders' Equity & Retained Earnings

Retained Earnings: Growing from $7.9B (2021) to $9.6B (2025) — steady accumulation despite high payout ratio. Positive.

ROE: 122% — extremely high but ARTIFICIAL due to low equity base (depleted by buybacks). Buffett would adjust: using tangible equity + treasury stock, effective ROE is ~26% — still well above the 15% threshold and industry average of 12%.

No Preferred Stock: Confirms Buffett's criterion — companies with durable advantages don't need preferred stock.

PASSGrowing retained earnings, high effective ROE, no preferred stock. Strong capital allocation history.

Cash Flow & Capital Expenditure

CAPEX/Earnings: At 56.3%, this EXCEEDS Buffett's 50% threshold. FY2025 capex of $1.14B was elevated due to "Powering Care" transformation investments (up from $721M in FY2024). This is likely TEMPORARY — pre-transformation capex was $766-876M (37-43% of earnings).

Operating Cash Flow: Consistently positive at $2.7-3.5B annually. Strong cash generation from operations.

CAUTIONCAPEX/Earnings above 50% currently but likely temporary (transformation). Historical levels were acceptable.

Source: stockanalysis.com/stocks/kmb/financials/cash-flow-statement (Jul 17, 2026)

P/E Ratio & Valuation

Intrinsic Value (15%)

P/E Analysis: At 16.8x TTM, KMB is well below the 40x flag level. The valuation is reasonable for a mature consumer staple. Forward P/E of 14.4x suggests modest growth is expected.

vs. Peers: KMB (16.8x) is significantly cheaper than PG (21.6x), CL (24.8x), and CHD (27.6x). The discount reflects lower growth expectations.

Intrinsic Value (Buffett method): Using 6% forward CAGR, 18x avg P/E, discounted at 15% = $48.35. Current price of $108.35 is 124% ABOVE this value. KMB does NOT offer 15% returns from current levels.

FAILPrice significantly exceeds Buffett intrinsic value. Cannot achieve 15% annual return at $108.35.

10-Year Projection

Scenario EPS CAGR Future EPS Future Price (18x) Annual Return Total w/Div

Conclusion: Even in the BULL case (8% EPS growth, which exceeds historical performance), total return with dividends reaches only 12.9% — still below Buffett's 15%. KMB cannot be a Buffett-style investment at current prices.

Right Price for 15% Return: $48-66 per share (depending on assumptions). Current price would need to decline 39-55%.

Investment Decision

HOLD — Income Investment Only

KMB possesses durable competitive advantage characteristics (consumer monopoly, brand dominance, repeat-purchase products) but does NOT meet Buffett's 15% annual return threshold at current prices. Projected total return of ~10.9% (including 4.81% dividend) makes this an income investment, not a growth compounder.

Buy Price for 15% return: $48-66 | Current: $108.35 | Gap: -55% to -39%

Buffett Analysis Scorecard

Test Result Value Threshold

Gross Profit Margin FAIL 36.0% >40%

← Main Page Análisis Graham Buffett Sowell Metodología About

Kimberly-Clark Corporation (KMB)

Security Analysis — Benjamin Graham Method

⚠️ CLASSIFICATION: SPECULATION (BY PRICE) Excellent company but price approaches Graham's maximum investment threshold — limited margin of safety

GRAHAM INTRINSIC VALUE THERMOMETER

◄ BARGAIN ►◄ INVESTMENT ►◄ SPECULATION ►◄ OVERVALUED ►

$49.52$74.29$118.86$140+

▲ CURRENT PRICE: $108.35 — IN SPECULATION ZONE (upper range)

(Sum: $5.99+$6.40+$4.03+$6.24+$6.87+$5.35+$5.72+$5.21+$7.55+$6.07 = $59.43 ÷ 10)

Investment vs. Speculation Classification

Analysis: KMB at $108.35 trades at 18.2x its 10-year average EPS of $5.94 — below the absolute maximum of 20x but well above the 12.5x normal multiplier. The P/E is within the "speculative zone" (12.5x–20x) but not yet beyond the maximum. However, the company's sub-1.0 current ratio and highly leveraged balance sheet (D/E of 4.3x) introduce financial risk that Graham would penalize.

⚠️ VERDICT: SPECULATION BY PRICE — Price exceeds normal value significantly. Limited margin of safety. Financial structure is aggressive.

Sources: stockanalysis.com (Jul 17, 2026), macrotrends.net (Jul 2026)

Earning Power Analysis (10-Year Record)

Year EPS (Diluted) Net Income ($M) Revenue ($M) Net Margin

Income Statement Deep Dive

Gross Margin (FY2025)

Operating Margin (FY2025)

Depreciation (FY2025)

Gross Profit Trend: Margins improved from ~30.8% (2021-2022) to 36-37% (2024-2025) due to pricing power, cost savings from the "Powering Care" transformation, and divestiture of lower-margin international tissue operations.

Depreciation Adequacy: D&A of $805M on $6.8B net PP&E implies ~11.9% depreciation rate, consistent with capital-intensive consumer goods manufacturing. Adequate.

Balance Sheet Analysis — Asset Value

Net Current Asset Value/Share

Analysis: KMB's balance sheet is liability-heavy. Total liabilities of $15.4B vs. equity of $1.65B reflects decades of aggressive share buybacks ($6.0B in treasury stock) and debt-funded returns to shareholders. The negative tangible book value means ALL of KMB's equity consists of intangibles (goodwill + other).

Net Current Asset Value: At -$30.53/share, KMB fails this test completely. Current liabilities ($7.1B) exceed current assets ($5.3B).

❌ FAIL — Negative net current asset value. No asset floor for investment protection.

Source: stockanalysis.com/stocks/kmb/financials/balance-sheet (Jul 17, 2026)

Debt and Financial Structure Analysis

LT Debt Payoff (Avg NI)

Long-term Debt Payoff Test: $6,474M LT debt ÷ $2,044M avg net income = 3.2 years. PASSES Graham's ≤4 year test.

Current Ratio: 0.75 — FAILS Graham's 2.0 minimum for industrials.

Debt Trajectory: Total debt reduced from $8,574M (2021) to $7,168M (2025) — positive deleveraging trend ($1.4B over 4 years).

Treasury-Stock Adjusted D/E: $7.2B / ($1.65B + $6.0B) = 0.94x — more representative of economic leverage.

Intrinsic Value Calculation

Intrinsic Value Range

Margin of Safety vs. Normal

Method: Normal earning power: $5.94/share (10-year average EPS). Conservative estimate (12.5x): $74.29. Optimistic estimate (20x): $118.86. Midpoint: $96.57. Quality premium justified for 54-year dividend streak and dominant brands — fair multiple ~15-16x = $89-95.

Margin of Safety: At $108.35, price exceeds midpoint intrinsic value by 12.2%. Against normal value ($74.29), overvalued by 45.9%. NO margin of safety.

❌ FAIL — No margin of safety. Price exceeds midpoint intrinsic value. Graham requires ≥33% discount.

Comparative Analysis

Company P/E (TTM) Dividend Yield Market Cap Net Margin

Qualitative Factor Assessment

Business Stability: HIGH. Diapers, tissues, and feminine care are non-discretionary repeat purchases.

Competitive Position: Strong brand portfolio (Huggies #1/#2 globally, Kleenex dominant in tissue, Kotex strong). Competes against PG and private label.

Transformation Risk: ELEVATED. "Powering Care" transformation is most significant restructuring in 150+ years. Arbex JV (launched Jul 1, 2026) divests majority control of international tissue.

Industry Outlook: Neutral. Population growth supports demand but birth rate declines and private label are headwinds.

⚠️ CAUTION — Inherently stable business undergoing significant structural transformation.

Dividend and Shareholder Policy

Consecutive Increases

Dividend King: 54 consecutive years of increases, 92 years of uninterrupted payments. Payout ratio ~80%. FCF payout ~101% for FY2025 — spending more on dividends than FCF generated (elevated capex).

Sustainability Warning: Current dividend exceeds free cash flow. Sustainable only if capex normalizes from elevated $1.1B+ transformation spending.

⚠️ CAUTION — Exceptional history but current payout exceeds FCF. Sustainability depends on capex normalization.

Sources: marketbeat.com (Jul 16, 2026), 247wallst.com (Feb 9, 2026)

Special Situations and Warning Signs

Accounting Manipulation: No red flags detected. Tax rates 21-29%, consistent with US corporate rates.

Hidden Value: 49% stake in Arbex JV (~$1.67B); brand portfolio not fully reflected in book value.

Hidden Risks: Transformation execution risk; elevated capex; commodity exposure; negative working capital.

⚠️ CAUTION — No manipulation detected. Hidden value in JV stake. Elevated execution risk.

Sources: sec.gov (Jun 2025), stockanalysis.com (Jul 2026)

← Main Page Análisis Graham Buffett Sowell Metodología About

Kimberly-Clark Corporation (KMB)

Economic Analysis — Thomas Sowell Framework

Personal Care & Tissue

ALCISTA (Moderately Bullish)

Transparent price signals, natural consumer monopoly position, efficient resource flow through competitive supply chain. Transformation unlocks margin expansion. No significant government dependency or distortion. Competitive position protected by brand loyalty and scale, not artificial barriers.

Critical Scarce Resources

Resource % of Cost Price Trend (5yr) Substitutes Risk

Pulp (wood fiber) ~25% Declining from 2022 peaks [CONFIRMED — 10-K raw material disclosures] Recycled fiber, bamboo (10-20% premium) Low

Petroleum-based materials (SAP, plastics) ~15% Volatile, currently stable [REPORTED — commodity indices] Bio-based alternatives (higher cost) Medium

Energy (manufacturing) ~8% Stable [REPORTED — EIA data] Renewable sources (being adopted) Low

Labor (manufacturing + distribution) ~20% Rising (wage inflation) [INFERRED — industry trend] Automation (capital investment required) Medium

Mapping of Leading Suppliers

Input Market Structure Key Suppliers Price Signals

Pulp COMPETITIVE (many producers globally) Suzano, Fibria, Canfor, Resolute, Mercer Transparent, market-driven [CONFIRMED — 10-K notes competitive sourcing]

SAP (superabsorbents) OLIGOPOLY (3-5 major producers) BASF, Nippon Shokubai, Evonik, LG Chem Moderately transparent [INFERRED — industry structure]

Petroleum-based plastics COMPETITIVE (global commodity) Multiple petrochemical producers Transparent, exchange-traded derivatives

Suzano Relationship: The Arbex JV (51% Suzano, 49% KMB) creates an interesting dynamic. Suzano is the world's largest pulp producer AND now KMB's JV partner for international tissue. This provides KMB favorable access to a critical input. [CONFIRMED — SEC filing Jun 5, 2025]

Price Signals — The Pass-Through Test

Dimension Trend Signal

Input Prices (costs) Declining/Stable (post-2022 normalization) Favorable — margin expansion opportunity

Output Prices (product pricing) Stable to slightly up (mix improvement) Pricing power maintained

Margin Signal EXPANDING (GPM 30.8% → 36.0% over 3 years) Company capturing value

CRITICAL PASS-THROUGH TEST:

Incentives and Opportunity Cost

Investor's Opportunity Cost:

KMB total return estimate: ~10.9%/yr (6.1% price + 4.81% dividend)

10-Year Treasury: 4.55% (risk-free rate) — KMB offers ~6.4% premium

S&P 500 historical: ~10%/yr — KMB roughly matches but with lower volatility

Management Incentives:

Government Intervention and Distortions

Subsidies: No significant direct government subsidies identified. KMB's profitability is derived entirely from consumer demand for hygiene products, not government programs. [CONFIRMED — 10-K shows no material government grants or subsidies in revenue]

Tariffs: KMB benefits modestly from US tariffs on imported Chinese consumer goods (competitors face higher costs to import). However, this is NOT material to KMB's competitive position — domestic manufacturing is the primary advantage. [INFERRED — general trade policy environment]

Regulation: FDA oversight on personal care products acts as a mild BARRIER TO ENTRY (compliance costs deter small competitors). Environmental regulations (EPA) affect all manufacturers equally — pass-through possible. [CONFIRMED — 10-K Item 1A Risk Factors discusses regulatory environment]

CRITICAL TEST: If ALL government intervention disappeared tomorrow, would KMB still be profitable? ABSOLUTELY YES. Consumer demand for diapers, tissues, and feminine care exists independent of any government action. KMB's brands would maintain market position based on consumer preference, not protection.

⚡ HEAVY WEIGHT FACTOR — NO SUBSIDY DEPENDENCY. Profitability is from REAL market demand. No artificial distortion supports this company's earnings. BULLISH signal (counts as 2).

Systemic Risk and Global Interconnectivity

Risk Factor Exposure Assessment

Geographic Concentration ~60% North America post-Arbex [INFERRED — based on segment restructuring] Moderate (concentrated but stable market)

Credit/Debt Dependence $7.2B total debt, strong cash flow coverage Low (debt serviceable, deleveraging)

Currency Exposure Reduced post-Arbex (less international) Low

Supply Chain Disruption Diversified manufacturing base Low

Competition and Market Position

Market Structure: OLIGOPOLY with differentiation. Top 3-4 players (PG, KMB, Essity, Unicharm) control the majority of global market for branded hygiene products. Private label provides competitive pressure on price but not on brand loyalty.

Market Position by Segment:

Diapers (Huggies): #2 globally behind PG's Pampers. Strong brand loyalty. [REPORTED — industry analyses]

Tissue (Kleenex): #1 brand name globally (now partially in Arbex JV for international)

Feminine Care (Kotex): Top 3 globally

Scale, Specialization, and Efficiency

Economies of Scale: KMB is still operating in economies-of-scale territory. The "Powering Care" transformation is explicitly designed to INCREASE efficiency by: (1) divesting lower-margin operations (IFP → Arbex), (2) consolidating manufacturing, (3) investing in automation. [CONFIRMED — prnewswire.com Jan 27, 2026 earnings release]

Specialization: Post-transformation, KMB is MORE specialized — focused on North American personal care and select international personal care markets. This is appropriate specialization per Sowell's framework (do what you do best, buy the rest from specialists).

Operational Efficiency Signals:

Gross margin expansion: 30.8% → 36.0% (2022-2025) — efficiency improving

Operating margin expansion: 13.3% → 14.3% despite revenue decline — doing more with less

Profits, Losses, and Management

Nature of Profits: KMB's profits derive from REAL market demand for hygiene products, NOT from subsidies or artificial protection. Profit margins of 12-15% on $16B+ revenue indicate sustainable, efficiency-driven earnings. These are NOT extraordinary profits that would attract massive new competition — the market is mature with established barriers.

CEO Mike Hsu executing bold transformation (Arbex JV, focus shift) — demonstrates adaptability [CONFIRMED — public announcements]

Insider ownership only 0.26% — limited skin in the game [CONFIRMED — stockanalysis.com]

54 years of dividend increases demonstrates institutional discipline

Active deleveraging ($1.4B debt reduction 2021-2025) shows fiscal responsibility

Sowell Conclusion — Verdict

Factor Type Factor Direction Weight

HEAVY Pass-Through Test (Phase 3) BULLISH ✅ ×2

HEAVY Natural Monopoly Classification (Phase 7) BULLISH ✅ ×2

HEAVY No Subsidy Dependency (Phase 5) BULLISH ✅ ×2

Standard Input costs declining/stable (Phase 1) BULLISH ×1